Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Opioid-Induced Constipation (OIC) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Opioid-Induced Constipation (OIC) Overview | 8 | 1 |
| Pipeline Products for Opioid-Induced Constipation (OIC) Comparative Analysis | 9 | 1 |
| Opioid-Induced Constipation (OIC) Therapeutics under Development by Companies | 10 | 1 |
| Opioid-Induced Constipation (OIC) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Opioid-Induced Constipation (OIC) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Opioid-Induced Constipation (OIC) Products under Development by Companies | 15 | 1 |
| Opioid-Induced Constipation (OIC) Products under Investigation by Universities/Institutes | 16 | 1 |
| Opioid-Induced Constipation (OIC) Companies Involved in Therapeutics Development | 17 | 7 |
| Develco Pharma Schweiz AG | 17 | 1 |
| Ironwood Pharmaceuticals, Inc. | 18 | 1 |
| Shionogi &Co., Ltd. | 19 | 1 |
| Sucampo Pharmaceuticals, Inc. | 20 | 1 |
| Synergy Pharmaceuticals, Inc. | 21 | 1 |
| Theravance Biopharma, Inc. | 22 | 1 |
| Valeant Pharmaceuticals International, Inc. | 23 | 1 |
| Opioid-Induced Constipation (OIC) Therapeutics Assessment | 24 | 10 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Combination Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 30 |
| (axelopran sulfate + oxycodone hydrochloride) Drug Profile | 34 | 1 |
| axelopran sulfate Drug Profile | 35 | 2 |
| dolcanatide Drug Profile | 37 | 3 |
| linaclotide Drug Profile | 40 | 7 |
| lubiprostone Drug Profile | 47 | 8 |
| methylnaltrexone bromide Drug Profile | 55 | 4 |
| methylnaltrexone bromide Drug Profile | 59 | 1 |
| naldemedine tosylate Drug Profile | 60 | 2 |
| naloxone hydrochloride PR Drug Profile | 62 | 1 |
| Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC Drug Profile | 63 | 1 |
| Opioid-Induced Constipation (OIC) Dormant Projects | 64 | 1 |
| Opioid-Induced Constipation (OIC) Discontinued Products | 65 | 1 |
| Opioid-Induced Constipation (OIC) Product Development Milestones | 66 | 8 |
| Featured News &Press Releases | 66 | 1 |
| Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation | 66 | 1 |
| May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation | 66 | 1 |
| Apr 04, 2016: Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR | 67 | 1 |
| Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation | 67 | 1 |
| Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation | 67 | 1 |
| Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation | 68 | 1 |
| Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015 | 69 | 1 |
| Sep 08, 2015: Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR | 70 | 1 |
| Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation | 70 | 1 |
| Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients | 71 | 1 |
| Jun 03, 2015: RELISTOR Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation | 71 | 1 |
| May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation | 71 | 1 |
| May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week | 72 | 1 |
| Apr 24, 2015: RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain | 72 | 1 |
| Mar 30, 2015: Shionogi Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation | 73 | 1 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |